Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

June 2nd 2012

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

June 1st 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

NSAIDs for Skin Cancer Prevention

May 31st 2012

Researchers find that people who took NSAIDs were less likely to develop skin cancer.

Krista Rubin on Understanding Ipilimumab's Toxicities

May 24th 2012

Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Ipilimumab Demonstrates Activity in Patients With Brain Metastases

May 22nd 2012

Ipilimumab generates antitumor activity in some patients with advanced melanoma whose disease has metastasized to the brain without resulting in unexpected toxicities.

Melanoma Mortality Is Related to Dermatologist Density

May 18th 2012

Within a given county in the United States, the presence of a dermatologist is associated with a lower melanoma mortality rate compared with counties where there is no dermatologist.

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

May 17th 2012

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

May 16th 2012

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Dr. Chapman on BRAF/MEK Combination for Melanoma

May 16th 2012

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Metastatic Melanoma: Timely Approval of Yervoy

May 9th 2012

After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.

Vemurafenib Study Builds on Positive Response Data

May 7th 2012

Vemurafenib continues to demonstrate clinical response and overall survival benefits for patients with metastatic melanoma.

Krista Rubin on Managing Ipilimumab-related Dermatitis

May 6th 2012

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

6-Fold Melanoma Increase Is Found Among Young Adults

April 24th 2012

Cutaneous melanoma is becoming increasingly common in young adults, with an 8-fold increase among young adult females and a 4-fold increase among young adult males.

Special Report on Immunotherapy: Managing Yervoy's Side Effects

March 21st 2012

As an immunotherapy, Yervoy presents a unique set of side effects and it was approved along with a Risk Evaluation and Mitigation Strategy to address these events.

Vemurafenib Doubles Median Survival in Metastatic Melanoma Patients

March 5th 2012

Vemurafenib nearly doubles the median OS in more than 50% of patients with BRAF V600-mutated metastatic melanoma.

Targeted Therapies Yield Most Promising Results: A New Era in Melanoma Treatment Has Begun

February 8th 2012

Melanoma is one of the most frequent cancers; more than 2 million Americans are treated for skin cancer annually.

Melanoma Breakthroughs Among Top 2011 Cancer Advances

January 31st 2012

Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.